These data therefore provide a rationale for the development of novel therapeutic strategies for SSc and SLE that will aim to restore TLR9 function in B cells to maintain both central and peripheral B-cell tolerance and suppress autoimmune manifestations. The gene discussed is TLR9; the disease is systemic sclerosis.